Avanir Pharmaceuticals Inc (NASDAQ:AVNR)
During the Trading Day
| 3.40 |  +0.15 / +4.62% |
Data as of 4:00pm ET | Day’s Change |
During After-Hours Switch to standard view »
| 3.40 |  0.00 / 0.00% |
Volume: 34.7K |
Latest AVNR News | Press Releases
| July Options Now Available For Avanir Pharmaceuticals (AVNR) May 20 / TheStreet.com | Wider-than-Expected Loss at Avanir - Analyst Blog May 09 / Zacks.com |
| Avanir Pharmaceuticals Increases Sales but Misses Estimates on Earnings May 09 / MotleyFool.com |
Today’s Trading
| Previous close | 3.25 |
| Today’s open | 3.20 |
| Day’s range | 3.15 - 3.40 |
| Volume | 901,211 |
| Average volume (3 months) | 1,214,099 |
| Market cap | $471.6M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/23/2013
Growth & Valuation
| Earnings growth (last year) | +11.76% |
| Earnings growth (this year) | +19.37% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +293.25% |
| P/E ratio | NM |
| Price/Sales | 10.34 |
| Price/Book | 12.04 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| SCRSimcere Pharmaceutic... | +0.03 | +0.32% |
| DVAXDynavax Technologies... | +0.01 | +0.40% |
| HITKHi-Tech Pharmacal Co... | +0.57 | +1.69% |
| MACKMerrimack Pharmaceut... | +0.15 | +2.94% |
Data as of 4:09pm ET, 05/23/2013
Financials
| Next reporting date | August 7, 2013 |
| EPS forecast (this quarter) | -$0.09 |
| Annual revenue (last year) | $41.3M |
| Annual profit (last year) | -$59.7M |
| Net profit margin | -144.75% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
President, Chief Executive Officer & Director Keith A. Katkin, MBA, CPA |
Secretary & Vice President-Finance Christine G. Ocampo, CPA |
Corporate headquarters Aliso Viejo, California |
Forecasts
